Kura Oncology

Emerging AML Therapies Will Revolutionize Targeted Cancer Care

AnalystHighTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

07 Aug 25

Updated

07 Aug 25

AnalystHighTarget's Fair Value

US$40.00

84.5% undervalued

07 Aug

US$6.20

-67.4%

-2.5%

Author's Valuation

US$40.0

84.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$40.0

84.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

43.04%

Biotech revenue growth rate

11.40%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$384.92m

Earnings '28

15.79x

PE Ratio '28

US$6.08b

Market Cap '28

US$6.08b

Market Cap '28

124.82m

No. shares '28

US$48.70

Share Price '28

US$48.70 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$40.00

Fair Value '25